TY - JOUR T1 - Diagnostic Performance of <sup>124</sup>I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 869 LP - 874 DO - 10.2967/jnumed.121.262797 VL - 63 IS - 6 AU - Manuel Weber AU - Jochen Schmitz AU - Ines Maric AU - Kim Pabst AU - Lale Umutlu AU - Martin Walz AU - Ken Herrmann AU - Christoph Rischpler AU - Frank Weber AU - Walter Jentzen AU - Sarah Theurer AU - Thorsten D. Poeppel AU - Nicole Unger AU - Wolfgang P. Fendler Y1 - 2022/06/01 UR - http://jnm.snmjournals.org/content/63/6/869.abstract N2 - 123/131I-metaiodobenzylguanidine (MIBG) scintigraphy has shown a high specificity for imaging pheochromocytoma and paraganglioma, but with low sensitivity because of low spatial resolution. 124I-MIBG PET may be able to overcome this limitation and improve the staging of patients with (suspected) pheochromocytoma. Methods: We analyzed the sensitivity, specificity, and positive and negative predictive values of 124I-MIBG PET in 43 consecutive patients with suspected (recurrence of) pheochromocytoma using histopathologic (nā€‰=ā€‰25) and clinical validation (nā€‰=ā€‰18) as the standard of truth. Furthermore, we compared the detection rate of 124I-MIBG PET versus contrast-enhanced (CE) CT on a per-patient and per-lesion basis in 13 additional patients with known metastatic malignant pheochromocytoma. Results: 124I-MIBG PET/CT was positive in 19 (44%) of 43 patients with suspected pheochromocytoma. The presence of pheochromocytoma was confirmed in 22 (51%) of 43. 124I-MIBG PET/CT sensitivity, specificity, and positive and negative predictive values were 86%, 100%, 100%, and 88%, respectively. 124I-MIBG PET was positive in 11 (85%) of 13 patients with malignant pheochromocytoma. Combined 124I-MIBG PET and CE CT detected 173 lesions, of which 166 (96%) and 118 (68%) were visible on 124I-MIBG PET and CE CT, respectively. Conclusion: 124I-MIBG PET detects pheochromocytoma with high accuracy at initial staging and a high detection rate at restaging. Future assessment of 124I-MIBG PET for treatment guidance, including personalized 131I-MIBG therapy, is warranted. ER -